Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes
Теплизумаб вызывает стойкие изменения в антиген-специфическом репертуаре у лиц с риском развития сахарного диабета 1 типа
2024-08-13
SCID: 54.1/4ptyq5nr
Discuss with AI
Autoreactive T cellsCD8+ T-cell exhaustionSingle-cell RNA sequencingTeplizumabType 1 diabetes
Figures from the paper
Abstract (AI)
BACKGROUNDTeplizumab, a non-FcR-binding anti-CD3 mAb, is approved to delay progression of type 1 diabetes (T1D) in at-risk patients. Previous investigations described the immediate effects of the 14-day treatment, but longer-term effects of the drug remain unknown.METHODSWith an extended analysis of study participants, we found that 36% were undiagnosed or remained free of clinical diabetes after 5 years, suggesting operational tolerance. Using single-cell RNA sequencing, we compared the phenotypes, transcriptome, and repertoire of peripheral blood CD8+ T cells including autoreactive T cells from study participants before and after teplizumab and features of responders and non-responders.RESULTSAt 3 months, there were transcriptional signatures of cell activation in CD4+ and CD8+ T cells including signaling that was reversed at 18 months. At that time, there was reduced expression of genes in T cell receptor and activation pathways in clinical responders. In CD8+ T cells, we found increased expression of genes associated with exhaustion and immune regulation with teplizumab treatment. These transcriptional features were further confirmed in an independent cohort. Pseudotime analysis showed differentiation of CD8+ exhausted and memory cells with teplizumab treatment. IL7R expression was reduced, and patients with lower expression of CD127 had longer diabetes-free intervals. In addition, the frequency of autoantigen-reactive CD8+ T cells, which expanded in the placebo group over 18 months, did not increase in the teplizumab group.CONCLUSIONThese findings indicate that teplizumab promotes operational tolerance in T1D, involving activation followed by exhaustion and regulation, and prevents expansion of autoreactive T cells.TRIAL REGISTRATIONClinicalTrials.gov NCT01030861.FUNDINGNational Institute of Diabetes and Digestive and Kidney Diseases/NIH, Juvenile Diabetes Research Foundation.
Key Findings
1
After five years, 36% of teplizumab-treated participants remained undiagnosed or free of clinical type 1 diabetes, suggesting operational tolerance.
2
Lower IL7R/CD127 expression was associated with longer diabetes-free intervals, linking this treatment-induced regulatory phenotype to clinical response.
3
Teplizumab induced early activation signatures in CD4+ and CD8+ T cells at three months, followed by reversal and reduced T-cell receptor and activation pathway expression at 18 months.
4
Teplizumab prevented the 18-month expansion of autoantigen-reactive CD8+ T cells observed in placebo-treated participants.
5
Treatment increased exhaustion- and immune-regulation-associated gene expression in CD8+ T cells, with pseudotime analysis indicating differentiation toward exhausted and memory states.
Research Object
Peripheral blood CD8+ T cells, including autoreactive T cells, in individuals at risk for type 1 diabetes treated with teplizumab
Research Subject
Persistent teplizumab-induced changes in T-cell phenotypes, transcriptional states, differentiation, and antigen-specific repertoire associated with operational tolerance and prevention of autoreactive T-cell expansion
Publication Details
Publication Date
2024-08-13
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest